1 - 10 of 421 Results
Condition Status ˆ Requirements ˇ Location Near You ˇ
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

111762-A Study of GSK1349572 versus Raltegravir (RAL) with Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
111762-A Study of GSK1349572 versus Raltegravir (RAL) with Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

117172-A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in human immunodeficiency virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
117172-A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in human immunodeficiency virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
Human Immunodeficiency Virus (HIV)
Recruiting
18+

To find a center near you, please provide a Country or Postal Code.

116483-Protocol to evaluate the public health value of maraviroc using the French hospital databaseon HIV infection (FHDH)
116483-Protocol to evaluate the public health value of maraviroc using the French hospital databaseon HIV infection (FHDH)
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

A4001067-Prospective Observational Epidemiologic Study of Maraviroc's Safety
A4001067-Prospective Observational Epidemiologic Study of Maraviroc's Safety
Human Immunodeficiency Virus (HIV)
Active, not recruiting
4-2

To find a center near you, please provide a Country or Postal Code.

APV20002-Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
APV20002-Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
Human Immunodeficiency Virus (HIV)
Active, not recruiting
2-18

To find a center near you, please provide a Country or Postal Code.

A4001031-An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
A4001031-An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

208569-Use and effectiveness of dolutegravir-based regimens in naïve and virologically suppressed ART-experienced individuals from the Cohort of the Spanish AIDS Research Network (CoRIS)
208569-Use and effectiveness of dolutegravir-based regimens in naïve and virologically suppressed ART-experienced individuals from the Cohort of the Spanish AIDS Research Network (CoRIS)
Hepatitis B
Active, not recruiting
15+

To find a center near you, please provide a Country or Postal Code.

NUC 30956-A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B alone
NUC 30956-A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B alone
Human Immunodeficiency Virus (HIV)
Recruiting
18+

To find a center near you, please provide a Country or Postal Code.

208983-Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
208983-Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

209035-Phase 2b, open-label, multicenter, rollover study to assess antiviral activity and safety of Long-acting Cabotegravir (CAB LA) plus Long-acting Rilpivirine (RPV LA), administered every 2 months (Q2M), in human immunodeficiency virus (HIV)- positive subjects from the LATTE study
209035-Phase 2b, open-label, multicenter, rollover study to assess antiviral activity and safety of Long-acting Cabotegravir (CAB LA) plus Long-acting Rilpivirine (RPV LA), administered every 2 months (Q2M), in human immunodeficiency virus (HIV)- positive subjects from the LATTE study